Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04510636
Status:
RECRUITING
Last Update Posted:
2024-03-22
First Post:
2020-08-09
Brief Title:
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab KEytruda in Combination With Bendamustine TREanda in RelapsedRefractory Hodgkin Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed cancer that has come back or started getting worse or refractory cancer that is not responding or has stopped responding to treatment Hodgkin lymphoma
Detailed Description:
Pembrolizumab and bendamustine will be explored as a safe and effective treatment for these patients
Although current treatment options are available for patients in the relapsed state once these therapies fail or are not tolerated treatment options are quite limited
Pembrolizumab and bendamustine have both shown activity when used as a single agent as treatment for Hodgkin Lymphoma Their side effect profiles also do not overlap which makes them ideal to combine with an intent to increase the amount and duration of complete responses while limiting the toxicities experienced by patients
Although current treatment options are available for patients in the relapsed state once these therapies fail or are not tolerated treatment options are quite limited
Pembrolizumab and bendamustine have both shown activity when used as a single agent as treatment for Hodgkin Lymphoma Their side effect profiles also do not overlap which makes them ideal to combine with an intent to increase the amount and duration of complete responses while limiting the toxicities experienced by patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CAPCR 20-5231 | OTHER | University Health Network | None |